Validity and Reliability of the Turkish Version of National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18) and Neurotoxicity-4 (NTX-4) for Patients with Advanced Ovarian Cancer

Table 3

Test-retest reliability of NFOSI-18 and NTX-4.

	Items	Test (mean ± SD) (n = 62)	Retest (mean ± SD) (n = 62)	ICC (95% CI)	SEM in 95% CI
NFOSI-18
DRS-physical (0–36)	9	27.4 ± 7.0	29.1 ± 6.0	0.90 (0.84–0.93)	2.21 (2.80–1.85)
DRS-emotional (0–4)	1	2.7 ± 1.2	2.8 ± 1.0	0.86 (0.78–0.91)	0.44 (0.56–0.36)
Treatment side effect (0–20)	5	17 ± 3.5	18.3 ± 2.0	0.73 (0.59–0.82)	2.7 (2.24–1.48)
Function/well-being (0–12)	3	9.5 ± 2.7	10.0 ± 2.6	0.66 (0.49–0.78)	0.5 (1.21–1.92)
Total score (0–72)	18	55.9 ± 13.4	60.0 ± 9.1	0.93 (0.88–0.95)	3.54 (2.99–4.64)
NTX-4
Total score (0–16)	4	11.5 ± 4.2	11.8 ± 4.2	0.90 (0.85–0.94)	1.32 (1.62–1.02)

NFOSI-18: the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Ovarian Cancer Symptom Index-18 Item Version, NTX-4: Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity 4-item, DRS: disease-related symptom, n: number of participants, SD: standard deviation, ICC: intraclass correlation coefficient, CI: confidence interval, and SEM: standard error of measurement,  < 0.05.